Randomized, controlled, triple-blinded trial comparing the ability of inhaled nitric oxide and aerosolized epoprostenol with extended stability (iPGI2,Veletri®) to reduce the incidence of (1) right-sided heart failure after advanced left-heart replacement therapies (durable LVAD, heart transplantation); and (2) severe primary graft dysfunction after lung transplantation.